Report Detail
Global Urological Cancer Therapeutics Drugs Market Insights, Forecast to 2025
- RnM2440411 |
- 12 April, 2019 |
- Global |
- 128 Pages |
- QYResearch |
- Pharma & Healthcare
The global Urological Cancer Therapeutics Drugs market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Urological Cancer Therapeutics Drugs market based on company, product type, end user and key regions.
This report studies the global market size of Urological Cancer Therapeutics Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Urological Cancer Therapeutics Drugs in these regions.
This research report categorizes the global Urological Cancer Therapeutics Drugs market by top players/brands, region, type and end user. This report also studies the global Urological Cancer Therapeutics Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Novartis
Pfizer
Johnson & Johnson
AstraZeneca
Astellas
Bristol-Myers Squibb
Abbott Laboratories
Celgene Corporation
Dendreon Corporation
Ferring Pharmaceuticals
GlaxoSmithKline plc
Indevus Pharmaceuticals Inc
Ipsen
Roche Healthcare
Sanofi S.A.
Market size by Product
Xofigo (radium Ra 223 dichloride)
Jevtana (cabazitaxel)
Inlyta (axitinib)
Votrient (pazopanib hydrochloride)
Sutent (sunitinib malate)
Zytiga (abiraterone acetate)
Xtandi (enzalutamide)
Opdivo (nivolumab)
Provenge (sipuleucel-T)
Market size by End User
Hospital
Medical Research Laboratory
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Urological Cancer Therapeutics Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Urological Cancer Therapeutics Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Urological Cancer Therapeutics Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Urological Cancer Therapeutics Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Urological Cancer Therapeutics Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Urological Cancer Therapeutics Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Urological Cancer Therapeutics Drugs Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Product
- 1.4.2 Xofigo (radium Ra 223 dichloride)
- 1.4.3 Jevtana (cabazitaxel)
- 1.4.4 Inlyta (axitinib)
- 1.4.5 Votrient (pazopanib hydrochloride)
- 1.4.6 Sutent (sunitinib malate)
- 1.4.7 Zytiga (abiraterone acetate)
- 1.4.8 Xtandi (enzalutamide)
- 1.4.9 Opdivo (nivolumab)
- 1.4.10 Provenge (sipuleucel-T)
- 1.5 Market by End User
- 1.5.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by End User
- 1.5.2 Hospital
- 1.5.3 Medical Research Laboratory
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Urological Cancer Therapeutics Drugs Market Size
- 2.1.1 Global Urological Cancer Therapeutics Drugs Revenue 2014-2025
- 2.1.2 Global Urological Cancer Therapeutics Drugs Sales 2014-2025
- 2.2 Urological Cancer Therapeutics Drugs Growth Rate by Regions
- 2.2.1 Global Urological Cancer Therapeutics Drugs Sales by Regions
- 2.2.2 Global Urological Cancer Therapeutics Drugs Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Urological Cancer Therapeutics Drugs Sales by Manufacturers
- 3.1.1 Urological Cancer Therapeutics Drugs Sales by Manufacturers
- 3.1.2 Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers
- 3.1.3 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI)
- 3.2 Urological Cancer Therapeutics Drugs Revenue by Manufacturers
- 3.2.1 Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2014-2019)
- 3.2.2 Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2014-2019)
- 3.3 Urological Cancer Therapeutics Drugs Price by Manufacturers
- 3.4 Urological Cancer Therapeutics Drugs Manufacturing Base Distribution, Product Types
- 3.4.1 Urological Cancer Therapeutics Drugs Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Urological Cancer Therapeutics Drugs Product Type
- 3.4.3 Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Urological Cancer Therapeutics Drugs Sales by Product
- 4.2 Global Urological Cancer Therapeutics Drugs Revenue by Product
- 4.3 Urological Cancer Therapeutics Drugs Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Urological Cancer Therapeutics Drugs Breakdown Data by End User
6 North America
- 6.1 North America Urological Cancer Therapeutics Drugs by Countries
- 6.1.1 North America Urological Cancer Therapeutics Drugs Sales by Countries
- 6.1.2 North America Urological Cancer Therapeutics Drugs Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Urological Cancer Therapeutics Drugs by Product
- 6.3 North America Urological Cancer Therapeutics Drugs by End User
7 Europe
- 7.1 Europe Urological Cancer Therapeutics Drugs by Countries
- 7.1.1 Europe Urological Cancer Therapeutics Drugs Sales by Countries
- 7.1.2 Europe Urological Cancer Therapeutics Drugs Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Urological Cancer Therapeutics Drugs by Product
- 7.3 Europe Urological Cancer Therapeutics Drugs by End User
8 Asia Pacific
- 8.1 Asia Pacific Urological Cancer Therapeutics Drugs by Countries
- 8.1.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Countries
- 8.1.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Urological Cancer Therapeutics Drugs by Product
- 8.3 Asia Pacific Urological Cancer Therapeutics Drugs by End User
9 Central & South America
- 9.1 Central & South America Urological Cancer Therapeutics Drugs by Countries
- 9.1.1 Central & South America Urological Cancer Therapeutics Drugs Sales by Countries
- 9.1.2 Central & South America Urological Cancer Therapeutics Drugs Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Urological Cancer Therapeutics Drugs by Product
- 9.3 Central & South America Urological Cancer Therapeutics Drugs by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Urological Cancer Therapeutics Drugs by Countries
- 10.1.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Countries
- 10.1.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Urological Cancer Therapeutics Drugs by Product
- 10.3 Middle East and Africa Urological Cancer Therapeutics Drugs by End User
11 Company Profiles
- 11.1 Novartis
- 11.1.1 Novartis Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Novartis Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
- 11.1.5 Novartis Recent Development
- 11.2 Pfizer
- 11.2.1 Pfizer Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Pfizer Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Pfizer Urological Cancer Therapeutics Drugs Products Offered
- 11.2.5 Pfizer Recent Development
- 11.3 Johnson & Johnson
- 11.3.1 Johnson & Johnson Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Johnson & Johnson Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Products Offered
- 11.3.5 Johnson & Johnson Recent Development
- 11.4 AstraZeneca
- 11.4.1 AstraZeneca Company Details
- 11.4.2 Company Business Overview
- 11.4.3 AstraZeneca Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Products Offered
- 11.4.5 AstraZeneca Recent Development
- 11.5 Astellas
- 11.5.1 Astellas Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Astellas Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Astellas Urological Cancer Therapeutics Drugs Products Offered
- 11.5.5 Astellas Recent Development
- 11.6 Bristol-Myers Squibb
- 11.6.1 Bristol-Myers Squibb Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products Offered
- 11.6.5 Bristol-Myers Squibb Recent Development
- 11.7 Abbott Laboratories
- 11.7.1 Abbott Laboratories Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Abbott Laboratories Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Products Offered
- 11.7.5 Abbott Laboratories Recent Development
- 11.8 Celgene Corporation
- 11.8.1 Celgene Corporation Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Celgene Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Products Offered
- 11.8.5 Celgene Corporation Recent Development
- 11.9 Dendreon Corporation
- 11.9.1 Dendreon Corporation Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Dendreon Corporation Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Products Offered
- 11.9.5 Dendreon Corporation Recent Development
- 11.10 Ferring Pharmaceuticals
- 11.10.1 Ferring Pharmaceuticals Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products Offered
- 11.10.5 Ferring Pharmaceuticals Recent Development
- 11.11 GlaxoSmithKline plc
- 11.12 Indevus Pharmaceuticals Inc
- 11.13 Ipsen
- 11.14 Roche Healthcare
- 11.15 Sanofi S.A.
12 Future Forecast
- 12.1 Urological Cancer Therapeutics Drugs Market Forecast by Regions
- 12.1.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Regions 2019-2025
- 12.1.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Regions 2019-2025
- 12.2 Urological Cancer Therapeutics Drugs Market Forecast by Product
- 12.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Product 2019-2025
- 12.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Product 2019-2025
- 12.3 Urological Cancer Therapeutics Drugs Market Forecast by End User
- 12.4 North America Urological Cancer Therapeutics Drugs Forecast
- 12.5 Europe Urological Cancer Therapeutics Drugs Forecast
- 12.6 Asia Pacific Urological Cancer Therapeutics Drugs Forecast
- 12.7 Central & South America Urological Cancer Therapeutics Drugs Forecast
- 12.8 Middle East and Africa Urological Cancer Therapeutics Drugs Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Urological Cancer Therapeutics Drugs Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Urological Cancer Therapeutics Drugs . Industry analysis & Market Report on Urological Cancer Therapeutics Drugs is a syndicated market report, published as Global Urological Cancer Therapeutics Drugs Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Urological Cancer Therapeutics Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
